Physiologically-based pharmacokinetic {PBPK) models for prediction of time-dependent enzyme inhibition (TDI): effect of diltiazem on midazolam and quinidine

Software: GastroPlus®
Division: Simulations Plus


Purpose of the study was to optimize a PBPK model to predict time­dependent and competitive inhibition of CYP 3A4 by diltiazem and to predict the effect on the pharmacokinetics (PK) of midazolam and quinidine.

By  Viera Lukacova, Walt S. Woltosz and Michael Bolger